Norbel Baby (6844) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 諾貝兒

Norbel Baby (6844) reported revenue of NT$315.5 million for Oct 2026, +1.1% year on year and +2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$3.14 billion (-0.4% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 32 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$275.8 million24/10Nov 2024 NT$278.7 millionDec 2024 NT$301 millionJan 2025 NT$311.5 millionFeb 2025 NT$277.3 million25/02Mar 2025 NT$281.9 millionApr 2025 NT$273.5 millionMay 2025 NT$309.2 millionJun 2025 NT$279.3 million25/06Jul 2025 NT$308 millionAug 2025 NT$331.3 millionSep 2025 NT$297.1 millionOct 2025 NT$311.9 million25/10Nov 2025 NT$280.8 millionDec 2025 NT$301.9 millionJan 2026 NT$280.7 millionFeb 2026 NT$284.5 million26/02Mar 2026 NT$283.4 millionApr 2026 NT$273.2 millionMay 2026 NT$309.7 millionJun 2026 NT$274 million26/06Jul 2026 NT$307.9 millionAug 2026 NT$332 millionSep 2026 NT$309.2 millionOct 2026 NT$315.5 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$315.5 million+1.1%+2.0%
Sep 2026NT$309.2 million+4.1%-6.9%
Aug 2026NT$332 million+0.2%+7.8%
Jul 2026NT$307.9 million+0.0%+12.4%
Jun 2026NT$274 million-1.9%-11.5%
May 2026NT$309.7 million+0.1%+13.4%
Apr 2026NT$273.2 million-0.1%-3.6%
Mar 2026NT$283.4 million+0.5%-0.4%
Feb 2026NT$284.5 million+2.6%+1.3%
Jan 2026NT$280.7 million-9.9%-7.0%
Dec 2025NT$301.9 million+0.3%+7.5%
Nov 2025NT$280.8 million+0.7%-10.0%
Oct 2025NT$311.9 million+13.1%+5.0%
Sep 2025NT$297.1 million+6.6%-10.3%
Aug 2025NT$331.3 million+15.1%+7.6%
Jul 2025NT$308 million+10.3%+10.3%
Jun 2025NT$279.3 million+0.8%-9.7%
May 2025NT$309.2 million+0.9%+13.1%
Apr 2025NT$273.5 million+0.6%-3.0%
Mar 2025NT$281.9 million+3.7%+1.7%
Feb 2025NT$277.3 million-4.8%-11.0%
Jan 2025NT$311.5 million+11.4%+3.5%
Dec 2024NT$301 million+0.9%+8.0%
Nov 2024NT$278.7 million+2.5%+1.1%
Oct 2024NT$275.8 million-4.8%-1.0%

Jan–Oct 2026 cumulative: NT$3.14 billion (-0.4% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Norbel Baby vs PEC / Norbel Baby vs Lotus Pharm / Norbel Baby vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

115/7/1取得合躍60%股權,屬共同控制下組織重整,視為自始取得,故重編去年比較期單月及累計營收數。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16